Physician profile
Stacie P Egan
NPI 1376062752
$169,502.52
in general payments reported to CMS, 2019-2025
37 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,783 · 2022: $4,537 · 2023: $26K · 2024: $37K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Travel and Lodging: $38K · Food and Beverage: $16K · Consulting Fee: $8,305 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,222.50 |
| Travel and Lodging | $37,769.50 |
| Food and Beverage | $15,743.43 |
| Consulting Fee | $8,305.26 |
| Education | $141.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84,928.50 | 2021-2025 | |
| Madrigal Pharmaceuticals | $65,951.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $7,228.37 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $2,436.36 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,645.14 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $1,280.10 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $640.28 | 2021-2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $584.16 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $561.59 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $546.49 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $517.76 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $474.25 | 2021-2025 | |
| Redhill Biopharma INC. | $414.38 | 2021-2024 | Talicia |
| Nestle Healthcare Nutrition INC. | $366.69 | 2021-2023 | |
| Genzyme Corporation | $365.14 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $219.32 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $185.61 | 2021-2024 | Dificid |
| Lilly USA, LLC | $174.74 | 2022-2025 | Omvoh |
| Braintree Laboratories, INC. | $132.27 | 2021-2025 | Suflave, Sutab |
| Celltrion USA INC. | $130.21 | 2024-2025 | Zymfentra, Vegzelma |
| Gilead Sciences, INC. | $84.17 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $82.42 | 2024-2025 | Iqirvo, Bylvay |
| Ferring Pharmaceuticals INC. | $77.82 | 2021-2024 | Rebyota |
| Fresenius Kabi USA, LLC | $70.38 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.43 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $48.98 | 2021-2025 | |
| Daiichi Sankyo INC. | $44.12 | 2021-2022 | |
| Sandoz INC. | $40.46 | 2024 | Hyrimoz |
| Boston Scientific Corporation | $35.47 | 2023 | Wavewriter Alpha Prime 16, Compliance Endokit |
| Amgen INC. | $31.27 | 2023 | Amjevita |
| Ironwood Pharmaceuticals, INC | $27.92 | 2024 | |
| Mylan Institutional INC. | $24.94 | 2023 | Hulio |
| Digestive Care, INC. | $22.33 | 2025 | Pertzye |
| Hologic Sales and Service, LLC | $19.02 | 2023 | Myosure Tissue Removal Device |
| Lucid Diagnostics INC. | $16.90 | 2023 | |
| Glaxosmithkline, LLC. | $12.87 | 2022 | |
| Amarin Pharma, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.